Abstract:Abstract Aims Galectin-3, a β-galactoside-binding lectin, is abnormally increased in cardiovascular disease. Plasma Galectin-3 receives a Class II recommendation for heart failure management and has been extensively studied for multiple cellular functions. The direct effects of Galectin-3 on platelet activation remain unclear. This study explores the direct effects of Galectin-3 on platelet activation and thrombosis. Methods and results A strong positive correlation between plasma Galectin-3 concentration and platelet aggregation or whole blood thrombus formation was observed in patients with coronary artery disease (CAD). Multiple platelet function studies demonstrated that Galectin-3 directly potentiated platelet activation and in vivo thrombosis. Mechanistic studies using the Dectin-1 inhibitor, laminarin, and Dectin-1−/− mice revealed that Galectin-3 bound to and activated Dectin-1, a receptor not previously reported in platelets, to phosphorylate spleen tyrosine kinase and thus increased Ca2+ influx, protein kinase C activation, and reactive oxygen species production to regulate platelet hyperreactivity. TD139, a Galectin-3 inhibitor in a Phase II clinical trial, concentration dependently suppressed Galectin-3-potentiated platelet activation and inhibited occlusive thrombosis without exacerbating haemorrhage in ApoE−/− mice, which spontaneously developed increased plasma Galectin-3 levels. TD139 also suppressed microvascular thrombosis to protect the heart from myocardial ischaemia–reperfusion injury in ApoE−/− mice. Conclusion Galectin-3 is a novel positive regulator of platelet hyperreactivity and thrombus formation in CAD. As TD139 has potent antithrombotic effects without bleeding risk, Galectin-3 inhibitors may have therapeutic advantages as potential antiplatelet drugs for patients with high plasma Galectin-3 levels. Key question Impact of Galectin-3 on platelet activation and arterial thrombus formation. Key finding Galectin-3 directly potentiates platelet activation and thrombus formation via Dectin-1 activation. TD139, a Galectin-3 inhibitor, protects the heart from myocardial ischaemia-reperfusion injury by suppressing Galectin-3-potentiated platelet activation and thrombosis without exacerbating haemorrhage in ApoE−/− mice. Take-home message Galectin-3 enhances platelet aggregation and thrombosis in patients with coronary artery disease; and Galectin-3 inhibitors may be considered for patients with high plasma Galectin-3 levels to prevent platelet hyperreactivity and thrombotic events.

Galectin-3 Induces the Phenotype Transformation of Human Vascular Smooth Muscle Cells Via the Canonical Wnt Signaling

Galectin-3-induced Oxidized Low-Density Lipoprotein Promotes the Phenotypic Transformation of Vascular Smooth Muscle Cells

Galectin-3 Derived from HucMSC Exosomes Promoted Myocardial Fibroblast-to-Myofibroblast Differentiation Associated with Β-Catenin Upregulation

Methyltransferase Like 3-Mediated N6-methylatidin Methylation Inhibits Vascular Smooth Muscle Cells Phenotype Switching Via Promoting Phosphatidylinositol 3-Kinase Mrna Decay.

Effects of galectin-3 on growth, migration and inflammation of endothe-lial cells

Galectin-3 Mediates Thrombin-Induced Vascular Smooth Muscle Cell Migration.

Galectin-3 induces vascular smooth muscle cells calcification via AMPK/TXNIP pathway

Endogenous and Exogenous Galectin-3 Promote the Adhesion of Tumor Cells with Low Expression of MUC1 to HUVECs Through Upregulation of N-cadherin and CD44

Galectin‐3 Exacerbates Ox‐ldl‐mediated Endothelial Injury by Inducing Inflammation Via Integrin Β1‐rhoa‐jnk Signaling Activation

Galectin-3 Accelerates the Progression of Oral Tongue Squamous Cell Carcinoma Via a Wnt/β-catenin-Dependent Pathway

Galectin-3 Mediates Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension

WNT3A ACTIVATES beta 1-INTEGRIN AND REGULATES MIGRATION AND ADHESION OF VASCULAR SMOOTH MUSCLE CELLS

Wnt3a activates β1-integrin and regulates migration and adhesion of vascular smooth muscle cells.

Myocardin related transcription factor and galectin-3 drives lipid accumulation in human blood vessels

Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update

Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation

Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study

Galectin-3 Mediates Pulmonary Vascular Remodeling in Hypoxia-Induced Pulmonary Arterial Hypertension

Role of galectin-3 in vascular calcification

Galectin-3 Contributes To Vascular Fibrosis In Monocrotaline-Induced Pulmonary Arterial Hypertension Ratmodel

Galectin-3 promotes calcification of human aortic valve interstitial cells via the NF-kappa B signaling pathway